| 杜焰家,温雅,张伟强,郭俊华.血清PCT与肺腺癌化疗患者肿瘤标志物的相关性.[J].中南医学科学杂志.,2021,(1):41-45. |
| 血清PCT与肺腺癌化疗患者肿瘤标志物的相关性 |
| Correlation between serum PCT and tumor markers in patients with lung adenocarcinoma chemotherapy |
| |
| DOI：10.15972/j.cnki.43-1509/r.2021.01.008 |
| 中文关键词: 肺腺癌 降钙素原 癌胚抗原 表皮生长因子受体 |
| 英文关键词:lung adenocarcinoma procalcitonin carcinoembryonic antigen epidermal growth factor receptor |
| 基金项目: |
|
| 摘要点击次数: 690 |
| 全文下载次数: 435 |
| 中文摘要: |
| 目的分析血清降钙素原(PCT)与肺腺癌化疗患者肿瘤标志物癌胚抗原(CEA)、表皮生长因子受体(EGFR)的关系。方法选取接受抗肿瘤治疗的51例肺腺癌患者,于化疗结束1~6月,参照肿瘤复发转移标准评估患者复发转移情况并分组。设计资料调查问卷,记录两组基线资料,检测并比较PCT、CEA、EGFR水平,分析PCT与CEA、EGFR的关系。结果化疗结束时51例肺腺癌患者血清PCT、CEA、EGFR水平均较抗肿瘤治疗前降低(P＜0.001)。随访1~6月,51例肺腺癌患者抗肿瘤治疗后13例复发转移；复发转移组血清PCT、CEA、EGFR水平均高于未复发转移组(P＜0.001)。经二元Logistic回归分析并建立多元回归模型,结果显示,血清PCT、CEA、EGFR高表达均是肺腺癌患者化疗后复发转移的影响因素(OR＞1,P＜0.05)。相关性分析结果显示,血清PCT与CEA、EGF之间均呈正相关(r＞0,P＜0.05)。绘制ROC曲线显示,血清PCT预测肺腺癌患者化疗后转移复发风险价值的AUC 为0.919,有一定预测价值,且在PCT cut-off值取0.095 μg/L时,预测价值最佳。结论肺腺癌患者化疗前血清PCT与CEA、EGFR水平均呈正相关,且PCT、CEA、EGFR高表达可能会增加化疗后肿瘤复发转移风险,动态监测血清PCT水平变化,有可能早期预测化疗后肿瘤转移复发风险。 |
| 英文摘要: |
| To analyze the correlation between serum procalcitonin (PCT) and carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR) in patients with chemotherapy of lung adenocarcinoma. MethodsA total of 51 patients with lung adenocarcinoma who were received anti-tumor therapy were selected as the research subjects; 1~6 months after chemotherapy, referred to the criteria of tumor recurrence and metastasis to evaluate the recurrence and metastasis of patients and divided them into groups; designed a data survey questionnaire, recorded the baseline data of the two groups, detected and compared the levels of PCT, CEA, EGFR, and analyzed the relationship between PCT and CEA, EGFR. ResultsAt the end of chemotherapy, the serum PCT, CEA, EGFR levels of 51 patients with lung adenocarcinoma were all decreased compared with those before anti-tumor therapy (P＜0.001). After 1~6 months of follow-up, among 51 patients with lung adenocarcinoma after anti-tumor therapy, 13 patients had recurrence and metastasis; the serum PCT, CEA, EGFR in the recurrence and metastasis group were higher than the non recurrence and metastasis group (P＜0.001). After binary Logistic regression analysis and a multiple regression model was established, the results showed that the overexpression of serum PCT, CEA, EGFR were all influencing factors for recurrence and metastasis in patients with lung adenocarcinoma after chemotherapy (OR＞1, P＜0.05). The correlation test results showed that serum PCT was positively correlated with CEA, EGFR (r＞0, P＜0.05). The ROC curve was drawn and showed that the AUC of serum PCT predicting the risk of metastasis and recurrence in patients with lung adenocarcinoma after chemotherapy were 0.919, which had certain predictive value. And when the PCT cut-off value was 0.095 μg/L, the best predictive value could be obtained. ConclusionThe serum PCT in patients with lung adenocarcinoma before chemotherapy is positively correlated with CEA, EGFR levels. And high level of PCT, CEA, EGFR may increase the risk of tumor recurrence and metastasis after chemotherapy. In the future, changes in serum PCT levels can be dynamically monitored to guide early clinical prediction, intervention in tumor metastasis and recurrence after chemotherapy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|